このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

FAMS を適応させて 1 型糖尿病の新興成人における CGM の使用を最適化する

2026年10月30日 更新者:Lindsay Mayberry、Vanderbilt University Medical Center

The goal of this clinical trial is to evaluate the efficacy of an adapted FAMS (Family/friend Activation to Motivate Self-care) intervention on CGM use among study participants who are CGM users. We will leverage the infrastructure of an NIDDK-funded RCT evaluating FAMS-T1D among N=280 emerging adults with T1D who have elevated hemoglobin A1c or elevated diabetes distress (NCT05820477). We anticipate at least 50% using CGM to be included in these analyses.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

FAMS (Family/friend Activation to Motivate Self-care) is a mobile phone-delivered intervention, based on Family Systems Theory, which helps adults with diabetes set behavioral goals and improve support received from friends and family for goal success. FAMS includes monthly phone coaching and text message support by FAMS coaches for the person with diabetes (PWD) and the option to enroll a support person (SP) to receive automated texts tailored to the self-care goals the person with T1D sets in coaching sessions. Adaptations specific to CGM include the option to set CGM use goals in coaching (and receive associated text support) and skill-building exercises during coaching to support data sharing relationships (e.g., establishing, setting and adjusting ground rules about communication).

Within the FAMS-T1D RCT (NCT05820477), we will test effects of FAMS-T1D on CGM use use relative to enhanced treatment as usual. We will evaluate effects on CGM use from baseline to post-intervention (6 months) as the primary endpoint. Study start date for the nested trial (NCT05854069) is the enrollment date of the first participant using a CGM. Since the goal of this trial is to assess effects of the adapted FAMS intervention on CGM use, the date participant CGM usage was confirmed is considered the enrollment date.

研究の種類

介入

入学 (推定)

140

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Los Angeles、California、アメリカ、90027
        • Children's Hospital of Los Angeles
    • Utah
      • Salt Lake City、Utah、アメリカ、84112
        • University of Utah

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~24年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

PERSONS WITH DIABETES

  • Ages 18-24
  • Have a diagnosis of T1D and has been taking insulin for at least one year
  • Comfortable sending and receiving texts
  • Can speak, read, and write in English
  • Meets one of the following two criteria: 1) has a most recent A1c value in the EHR that is 7.5% or higher (or missing) OR 2) screen positive for diabetes distress on the two-item Diabetes Distress Screen (DDS-2)
  • Using a continuous glucose monitor (CGM)

SUPPORT PERSONS

  • Age 18 or older
  • Can speak, read, and write in English or Spanish
  • Comfortable sending and receiving texts

Exclusion Criteria:

PERSONS WITH DIABETES

  • Has a condition that would prohibit study completion (intellectual disability, blindness or auditory limitations, severe mental illness)
  • Plans to live outside the country during the study period

SUPPORT PERSONS

  • Shares a phone with the person with diabetes
  • Plans to live outside of the country during the study period

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:FAMS-T1D

Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support persons will receive text messages that are tailored to the goal set by the person with type 1 diabetes.

All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.

Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.

他の名前:
  • 1 型糖尿病患者のセルフケアの動機付けとなる家族/友人の活性化

Quality digital resources about diabetes management provided upon enrollment and during the study.

プラセボコンパレーター:Digital resources for diabetes

All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

Quality digital resources about diabetes management provided upon enrollment and during the study.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
CGM frequency of use during the intervention period
時間枠:Baseline and 6 months post-baseline

Change in CGM frequency of use assessed by self-report on questionnaire; more frequent use/higher is better

Baseline and 6 months post-baseline
CGM frequency of use during the intervention period
時間枠:Baseline and 6 months post-baseline

Change in CGM frequency of use assessed by objective CGM data (% of time; higher is better)

Baseline and 6 months post-baseline
Gaps in CGM use
時間枠:6 months post-baseline

Length of gaps in CGM use as assessed by objective CGM data (measured in number of consecutive days without CGM data; higher is worse)

6 months post-baseline

二次結果の測定

結果測定
メジャーの説明
時間枠
CGM behavioral responses during the intervention period
時間枠:Baseline and 6 months post-baseline

Change in frequency of making behavioral changes in response to CGM data assessed by self-report; higher scores indicate more frequent response (better)

Baseline and 6 months post-baseline
Barriers to CGM use during the intervention period
時間枠:Baseline and 6 months post-baseline

Change in perceived influence of CGM on glycemic control scale assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)

Baseline and 6 months post-baseline
Barriers to CGM use during the intervention period
時間枠:Baseline and 6 months post-baseline

Change in perceived influence of CGM on social complications assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)

Baseline and 6 months post-baseline
CGM satisfaction during the intervention period
時間枠:Baseline and 6 months post-baseline

Change in CGM satisfaction assessed by Benefits of CGM scale; higher scores indicate more perceived benefits of CGM use (better)

Baseline and 6 months post-baseline

その他の成果指標

結果測定
メジャーの説明
時間枠
Data sharing during the intervention period
時間枠:6 months post-baseline

Number of data sharing relationships, between groups; more is better

6 months post-baseline
Satisfaction with data-sharing relationships
時間枠:6 months post-baseline

Satisfaction with data-sharing relationships assessed by CGM-Satisfaction Scale; higher scores are better

6 months post-baseline

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年4月30日

一次修了 (推定)

2027年1月31日

研究の完了 (推定)

2027年4月30日

試験登録日

最初に提出

2023年4月24日

QC基準を満たした最初の提出物

2023年5月9日

最初の投稿 (実際)

2023年5月11日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年10月30日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 220847
  • G-2203-05822 (その他の助成金/資金番号:The Leona M. and Harry B. Helmsley Charitable Trust)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

After study results are posted on clinical trials and published, de-identified data will be available upon requests made to the principal investigator.

IPD 共有時間枠

After study results are posted on clinical trials and outcomes published in a peer-reviewed journal, until 5 years later.

IPD 共有アクセス基準

Contact the principal investigator

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。